Semaglutide vs Tirzepatide
Medically reviewed by the Rite Aid Health Team · Last updated August 14, 2026
Semaglutide and tirzepatide are weekly prescription medicines with strong human evidence for chronic weight management. Tirzepatide targets GLP-1 and GIP and has produced greater average weight loss in head-to-head obesity research. Semaglutide has a longer record and outcome data across weight, cardiovascular, and other labeled uses.
Talk to a clinician about treatment options
GLP-1 medicines are prescription treatments. A licensed provider can review medical history and help select and manage an appropriate option. Peptides for weight loss provides the broader context.
At a glance
| Comparison | Semaglutide | Tirzepatide |
|---|---|---|
| Common goal | Weight management and cardiovascular-risk reduction in labeled groups | Weight management and obstructive-sleep-apnea treatment in labeled groups |
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| Evidence | Large randomized trials and approved labeling | Large randomized trials, approved labeling, and head-to-head obesity evidence |
| Route and timing | Weekly subcutaneous injection; a daily tablet has separate labeling | Weekly subcutaneous injection |
| Weight-loss starting dose | Wegovy injection starts at 0.25 mg weekly and increases in steps. Wegovy label | Zepbound starts at 2.5 mg weekly for four weeks and increases in steps. Zepbound label |
| Common side effects | Nausea, diarrhea, vomiting, constipation, and abdominal pain | Nausea, diarrhea, vomiting, constipation, abdominal pain, and injection reactions |
| Monitoring focus | GI tolerance, hydration, gallbladder or pancreatic symptoms, glucose medicines, and label warnings | The same core checks, plus oral-contraceptive guidance during dose escalation |
| Access and status | FDA-approved products by prescription | FDA-approved products by prescription |
When semaglutide is commonly considered
Semaglutide may fit when its specific approved indications, cardiovascular outcome evidence, insurance coverage, or a person’s prior response makes it the stronger match. The injectable and oral products have different instructions and should be compared by exact brand and indication.
When tirzepatide is commonly considered
Tirzepatide may fit when greater average weight loss is a priority and its dual-receptor mechanism, labeled indication, tolerability, coverage, and availability align with the person’s history. Averages help frame expectations but do not predict an individual result.
Why they are not combined
Both intensify incretin signaling and have overlapping gastrointestinal and glucose-lowering effects. Their labels do not recommend use with another GLP-1 receptor agonist, so the practical decision is which medicine to use and how to titrate it.
Related
Sources
Educational information only. Any GLP-1 treatment should be started and supervised by a licensed clinician.
For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.
FAQ
Tirzepatide has produced greater average weight loss in head-to-head obesity research. Individual response and tolerability vary.
Both injectable products are weekly, but their milligram doses and escalation steps are different and cannot be converted directly.